Athersys, Inc. (NASDAQ:ATHX)

CAPS Rating: 1 out of 5

ATHX News and Commentary

Caps

How do you think ATHX will perform against the market?

Add Stock to CAPS Watchlist

All Players

82 Outperform
24 Underperform
 

All-Star Players

5 Outperform
16 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top ATHX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Dublin43016 (< 20)
Submitted February 22, 2014

1. Recent regulatory changes to accelerate regenerative medicine use in Japan, will allow faster development of their products. CEO has already made several trips so as to get his ducks in a row.2.Second quarter results on phase II study on… More

zzlangerhans (99.83)
Submitted January 11, 2016

I just wasted close to an hour trying to translate pages of handwaving from the last Athersys conference call into actionable information. My takeaway: I'm supposed to ignore all the negative developments over the last few years with MultiStem… More

ATHX VS S&P 500 (SPY)

Fools bullish on ATHX are also bullish on:

Fools bearish on ATHX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ATHX.

Recs

0
Member Avatar SmartAce (99.94) Submitted: 10/19/2017 11:17:22 AM : Underperform Start Price: $1.94 ATHX Score: -2.46

A new study suggests that a future study will completely contradict this study.

Recs

0
Member Avatar jw2net (< 20) Submitted: 2/19/2016 11:33:47 AM : Outperform Start Price: $1.64 ATHX Score: -12.11

athx

Recs

0
Member Avatar zzlangerhans (99.83) Submitted: 2/3/2016 3:56:25 PM : Underperform Start Price: $1.28 ATHX Score: -19.91

Nothing new from my last red thumb except an inexplicable price rebound despite a crashing sector, so I'll repost my last pitch.

I just wasted close to an hour trying to translate pages of handwaving from the last Athersys conference call into actionable information. My takeaway: I'm supposed to ignore all the negative developments over the last few years with MultiStem because cytokines. Add this to the company's recent Enjo Kosai activities with various small Japanese pharmas and we have a market cap of 104M, cash of about 40M (inclusive of Healios upfront payment), and a probable inert stem cell soup therapy. Athersys share price is holding up while former darlings StemCells, Caladrius, and Pluristem are going down the toilet but don't expect that to last long as spec biotech remains volatile and new positive catalysts fail to appear during the year.

Leaderboard

Find the members with the highest scoring picks in ATHX.

Score Leader

drugtrader

drugtrader (96.64) Score: +193.45

The Score Leader is the player with the highest score across all their picks in ATHX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Billdo2211 77.58 12/8/2011 Underperform 3M $2.24 -11.16% +104.51% +115.67 0 Comment
kevrose31 81.55 1/10/2014 Underperform 1Y $4.08 -51.23% +39.23% +90.45 0 Comment
Halffrenzy 25.07 2/28/2014 Underperform 5Y $3.87 -48.58% +37.03% +85.61 0 Comment
Under5 < 20 2/6/2017 Outperform 5Y $1.16 +71.55% +11.90% +59.65 0 Comment
OttoBismarck 99.94 12/27/2013 Underperform 5Y $2.49 -20.08% +39.11% +59.19 0 Comment
Playa14 < 20 10/13/2015 Outperform 5Y $1.12 +77.68% +27.64% +50.04 0 Comment
MMCapitalMgmt 99.91 4/14/2016 Underperform 5Y $2.49 -20.08% +23.12% +43.20 0 Comment
Playa15 < 20 1/14/2016 Outperform 5Y $1.13 +76.11% +34.23% +41.88 0 Comment
GeneB43251 64.77 8/7/2015 Outperform 3Y $1.22 +63.11% +23.11% +40.00 0 Comment
z28quik < 20 4/27/2015 Outperform 3M $1.25 +59.84% +21.19% +38.65 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackwbbsecuriti < 20 9/13/2010 Outperform NS $3.00 -33.67% +127.49% -161.16 0 Comment

Featured Broker Partners